Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,237 total articles
Ferrari trades at a premium, but recent Q2 strength, a raised 2026 guide, aggressive buybacks and the most complete product lineup in decades justify owning the stock. This trade idea lays out an actionable long with entry, stop and target for a long-term holding (180 trading days), explains the fundamental drivers and balances the bull case with c…
Lyft is not the global behemoth Uber is, but it has carved an economically viable niche in North America. With free cash flow of roughly $1.12B, a market cap near $7.0B and a P/E around 2.3, Lyft looks attractively priced for a mid-term tactical long. Trade plan: enter $17.55, stop $15.00, target $22.00 over a mid term (45 trading days).
Kodiak Gas Services (KGS) combines fixed-revenue contract compression with expanding distributed power opportunities tied to AI and edge power demand. The company trades at about $61.05 with a $6.54B market cap, EV/EBITDA of ~12.9 and annual free cash flow of roughly $200M. We outline a long trade with clear entry, stop and target, plus the catalys…
Meta Platforms ($META) looks oversold relative to its fundamentals. The company generates roughly $41B in free cash flow, sports a 26% return on equity, and trades at ~22x earnings - not nosebleed for a company executing AI and ad monetization plays. This trade targets a mean-reversion and sentiment rebound into AI spending updates and ad cadence o…
Guardant Health is the leading pure-play liquid biopsy name. Recent FDA expansion for Guardant360 Liquid CDx, strong technicals, and large market projections for cancer biomarkers create a clear growth narrative. This trade idea outlines a long position with precise entry, stop and target, while laying out catalysts, valuation context and risks tie…
Nvidia's latest large acquisition meaningfully expands its addressable AI stack and strengthens its moat in data-center AI. We upgrade to a constructive rating and offer a long trade designed to capture post-deal integration upside while managing valuation risk.
UnitedHealth's post-2025 profit recovery looks sustainable as medical care ratios normalize and Optum tailwinds resume. The company trades below prior highs with solid free cash flow and dividend support. This trade idea lays out an entry at $405.00, a $460.00 target and an $388.00 stop for a long-term trade (180 trading days).
Rackspace is generating positive free cash flow today and trades at an attractive price-to-sales multiple. The stock has been punished this year on restructuring and disclosure noise, but the base business - particularly Private Cloud margins and a capital-light Public Cloud services model - still turns cash. If the company can monetize enterprise …
Intuitive Machines (LUNR) is trading near $16.28 after a string of favorable NASA awards and a $1.1 billion backlog. The company remains unprofitable but has record quarterly revenue and an attractive risk-reward for a tactical long with a 180 trading day horizon. This trade plan lays out entry at $16.20, stop at $13.50 and a $25 target tied to con…
BridgeBio (BBIO) just delivered more than clinical validation with Attruby's meaningful mortality benefit and continues to de-risk multiple near-term commercial events. With a strengthened balance sheet from a $1B preferred equity raise and positive Phase 3 data for BBP-418, the risk/reward tilts toward a long trade over the next 180 trading days. …
Ceres Power (CPWHF) trades at $5.90 with improving short-term technicals, massive short interest and very low public float liquidity — a setup that offers asymmetric upside if commercialization and partner rollouts continue. This trade idea is a long with a defined entry at $5.90, stop at $4.50 and target at $12.00 over a 180 trading-day horizon, s…
Corning has been one of 2026's biggest beneficiaries of the AI-data-center buildout. The recent digestion after a strong run gives investors a concrete entry. We upgrade GLW to Buy and lay out entry, stop, and target levels across defined horizons while flagging valuation and execution risks.
CVG reported accelerating revenue and margin improvement in Q2 2026 and has meaningful upside if it delivers on raised full-year guidance. The balance sheet refinancing completed in 2025 reduces near-term liquidity risk and leaves room for operational leverage to drive EPS and free cash flow improvement. This trade plan is a long with a $3.20 entry…
TTD is trading like a fallen growth name despite solid cash generation and a deeply oversold technical picture. This trade targets a mid-term rebound into valuation normalization while respecting an elevated execution risk backdrop tied to guidance and ad market headwinds.
Meta's stock at $606 offers a way to own a large-cap ad-business cash machine with meaningful embedded upside from AI investments and partnerships. Valuation is not absurd — P/E ~22 and FCF of $40.98B — and near-term headwinds look priced in. This trade targets upside as AI monetization accelerates and infrastructure investments begin to compound.
Rakuten (RKUNY) pulled back after an operating-profit miss, but underlying growth drivers - mobile rollout, fintech monetization, and strategic satellite and payments partnerships - justify a mid-term long trade. Technicals show constructive momentum; set a disciplined stop and a realistic target near the 52-week high.
Constellation Energy (CEG) just tightened the narrative investors have been waiting for: higher near-term guidance, a string of long-term PPAs (920 MW in Q2, including a 176 MW Walmart agreement), and renewed government support for nuclear are starting to show up in the equity. The company trades at roughly $99.6B market cap with EV/EBITDA ~14.5 an…
ACV Auctions ($ACVA) looks actionable on a long trade after recent quarters showed revenue growth, margin expansion and positive free cash flow. At a market cap near $1.28B and a stock trading around $7.30, the risk/reward favors a disciplined long with a $16 target over a 180-trading-day horizon, but investors must respect downside risks including…
Freeport-McMoRan (FCX) looks positioned to capture continued upside from a structurally tight copper market and recovering high-margin operations. Fundamentals and technicals align for a swing trade: entry at $69.00, stop at $62.50, target $82.00 over the next 45 trading days, with a medium risk profile.
Western Digital (WDC) sold off after earnings despite beating expectations and issuing robust forward guidance. The market has largely treated memory as a cyclical commodity; we think material long-term contracts and hyperscaler AI demand are underappreciated. Given solid EPS, strong free cash flow, low leverage and a non-extreme valuation, we init…
Microsoft remains one of the highest-quality technology franchises: a $3.88T market cap, double-digit free cash flow, and a fortress balance sheet that funds innovation across cloud, AI, and quantum. Short-term headlines about AI overspending and an uneven acceleration vs. cloud peers have pushed the stock below its recent peak. For investors who c…
TRX Gold's Buckreef is producing and the numbers support upside, but the stock trades on a mix of operational improvement and macro-dependent valuation. We propose a swing-long with tight risk controls to capture the next re-rating if guidance and ramp-up stay on track.
AI models are creating staggering daily token volumes and that data has to live somewhere. Western Digital sits squarely in the storage stack with strong guidance, improving fundamentals and healthy free cash flow. Technicals look beat up after a post-earnings pullback; this is a measured buy-the-dip trade with a clear entry, stop and target for a …
Bar Harbor Bankshares (BHB) has pushed up near its 52-week high on a mix of steady earnings, healthy capital metrics and an attractive dividend. The set-up today favors a mid-term long: buy near current levels, use a tight stop under the 50-day structural level, and target a breakout above prior highs. Risk-reward is asymmetric for patient traders …
Xenon Pharmaceuticals' positive Phase 3 X-TOLE2 results and planned New Drug Application submission in Q3 2026 make XENE a strong buy for investors willing to take a binary biotech trade. The company has backed efficacy data (53.2% median seizure reduction at 25 mg vs 10.4% for placebo), a sizable $650M capital raise, and a market cap near $6.3B. T…
